Allos Therapeutics Appoints David M. Stout to Its Board of Directors
24 March 2009 - 11:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative new
drugs for the treatment of cancer, today announced the appointment
of David M. Stout, former President, Pharmaceuticals at
GlaxoSmithKline, to the Company�s Board of Directors.
�We are pleased to welcome David to our Board of Directors and
look forward to benefiting from his guidance and contributions,�
said Paul L. Berns, President and CEO of Allos. �David�s 30-plus
years of experience in the pharmaceutical industry will be valuable
as we approach the potential commercialization of pralatrexate for
the treatment of patients with relapsed or refractory peripheral
T-cell lymphoma and continue to drive our product development and
commercialization plan for pralatrexate in both hematologic
malignancies and solid tumors.�
Mr. Stout, age 54, served most recently as President,
Pharmaceuticals at GlaxoSmithKline, where he was responsible for
the company�s global pharmaceutical operations, from January 2003
to February 2008. Prior to that, he served as President, U.S.
Pharmaceuticals at GlaxoSmithKline from 1999 to January 2003. He
served as Senior Vice President and Director, Sales and
Marketing-U.S. for SmithKline Beecham from 1996 to 1998. Prior to
that, Mr. Stout was President of Schering Laboratories, a division
of Schering-Plough Corporation, from 1994 to 1996. Mr. Stout also
held various executive and sales and marketing positions with
Schering-Plough Corporation from 1979, when he joined the company,
until 1994. Mr. Stout is a director of Airgas, Inc.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on
developing and commercializing innovative small molecule drugs for
the treatment of cancer. In February 2009, the Company announced
the final results from PROPEL, the Company�s pivotal Phase 2
(PROPEL) trial of pralatrexate in patients with relapsed or
refractory peripheral T-cell lymphoma (PTCL). The PROPEL trial was
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment (SPA) process.
Based on the results of the PROPEL trial, the Company intends to
submit a New Drug Application to the U.S. Food and Drug
Administration for pralatrexate for the treatment of relapsed or
refractory PTCL in the first half of 2009. The Company is also
investigating pralatrexate in patients with non-small cell lung
cancer, bladder cancer and a range of lymphoma sub-types. The
Company currently retains exclusive worldwide rights to
pralatrexate for all indications. For additional information,
please visit the Company�s website at www.allos.com.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics, Inc. News Articles